{"ok":true,"trend":{"id":465336,"platform":"news","region":"global","key":"enrollment closed: what moleculin’s miracle trial teaches about aml site execution","title":"Enrollment Closed: What Moleculin’s MIRACLE Trial Teaches About AML Site Execution","url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxON1NJX0daTml6WHhxWHJycHNpNm1seVNCQUwwN1FRQ2U0UzY3UHhfV3l6eno2Zm5EUGFFOTJFOHUxLXhMWGNBY0tGdUk4ajBhM1FkYmRWQzFJUTcwNDVGbG90YlZkZ0piR0Z1M29VX1dkcjFTdmx0Nk5QN1pwcnZKRkpVbjZRWjNocXVaU0F2SGVaUkhUZXc2b191a2JPcWRNak05d210cGh2UUxtamk5TTlJT0J2ZGZGQVlvNF8zeXY5aXFMOEZUVE5tRlNTOXpqUDRZZjNDNUVGUzNS?oc=5","first_seen":"2026-09-30T09:06:53.894595Z","last_seen":"2026-09-30T11:50:55.351445Z","last_rank":37,"peak_rank":37,"last_volume":null,"peak_volume":0,"seen_count":3,"score":0.6415625,"category_hint":"medicine","section":"health","category":"medicine","summary":"Moleculin Biotech has closed enrollment in its MIRACLE trial for acute myeloid leukemia, a step that shifts attention from recruiting patients to follow-up and data collection. Commentary around the milestone is focusing on what the trial's execution across clinical sites reveals about running complex AML studies. Observers in the oncology and biotech community are watching for next results.","why":"The trial reaching closed enrollment is a concrete milestone, and investors and oncology watchers are speculating on upcoming data.","tone":"neutral","entities":["Moleculin Biotech","MIRACLE trial","acute myeloid leukemia"],"summarized_at":"2026-09-30T09:07:54.057965Z","meta":{"via":"scan","lang":"en","term":"clinical trial","source":"The Clinical Trial Vanguard","published":"Wed, 30 Sep 2026 07:52:52 GMT"},"nw":null,"promo":null,"kind":null,"importance":null,"hidden":false,"hide_reason":null,"judged_at":null,"title_en":"Moleculin Closes Enrollment in MIRACLE Acute Myeloid Leukemia Trial","section_name":"Health","category_name":"Medicine","timeline":[{"captured_at":"2026-09-30T09:06:53.894595Z","rank":37,"volume":null},{"captured_at":"2026-09-30T10:28:53.107499Z","rank":37,"volume":null},{"captured_at":"2026-09-30T11:50:55.351445Z","rank":37,"volume":null}],"posts":[{"platform":"news","url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxON1NJX0daTml6WHhxWHJycHNpNm1seVNCQUwwN1FRQ2U0UzY3UHhfV3l6eno2Zm5EUGFFOTJFOHUxLXhMWGNBY0tGdUk4ajBhM1FkYmRWQzFJUTcwNDVGbG90YlZkZ0piR0Z1M29VX1dkcjFTdmx0Nk5QN1pwcnZKRkpVbjZRWjNocXVaU0F2SGVaUkhUZXc2b191a2JPcWRNak05d210cGh2UUxtamk5TTlJT0J2ZGZGQVlvNF8zeXY5aXFMOEZUVE5tRlNTOXpqUDRZZjNDNUVGUzNS?oc=5","author":"The Clinical Trial Vanguard","title":"Enrollment Closed: What Moleculin’s MIRACLE Trial Teaches About AML Site Execution","snippet":null,"posted_at":"2026-09-30T07:52:52Z","likes":null}],"elsewhere":[],"window":"7d"}}